Clinical trial
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell…
NCT00180895 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Terminated
Key facts
| NCT number | NCT00180895 |
|---|---|
| Title | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL |
| Official title | A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Burkitt Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 40 |
| Start date | Jun 1, 2004 |
| First posted | Sep 16, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: